Immunofusion SRL
The score of Immunofusion shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Total assets +1320 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Immunofusion's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 02 Jul 2026
- Year ended 31 Dec 2024filed on 19 Apr 2025
- Year ended 31 Dec 2023filed on 11 Apr 2024
Immunofusion's financial analysis
- Solvency-392.3%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Immunofusion
Immunofusion's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0804.563.629
- VAT number
- BE0804563629
- Peppol
- Registered · 0208:0804563629 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 04 Aug 2023
- Registered office
- 6041 Charleroi
- Latest accounts
- 2025 · filed on 02 Jul 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Immunofusion (SRL) has been based in Charleroi since 2023, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net loss of 42,606 € and equity of −126,049 €; its revenue is not published. Its solvency stands at -392.3%, below the median of its sector (58.2%).
Companies similar to Immunofusion
Companies in the same business, of comparable size and area, outside its group.
- Cmax Biotech Consulting Research and experimental development on natural sciences and engineering Hasselt · balance sheet 52,078 €
- AtomX Research and experimental development on natural sciences and engineering Chastre · balance sheet 32,717 €
- 1889 Consulting Research and experimental development on natural sciences and engineering Forest · balance sheet 42,356 €
- VKJ-Engineering Research and experimental development on natural sciences and engineering Heist-op-den-Berg · balance sheet 41,764 €
- Emelie Flemming-Parker Research and experimental development on natural sciences and engineering Tongeren-Borgloon · balance sheet 114,901 €
- Medisearch International Research and experimental development on natural sciences and engineering Bree · balance sheet 58,762 €
- Åtelier Salvesen Research and experimental development on natural sciences and engineering Saint-Gilles · balance sheet 100,983 €
- Coherence All other professional, scientific and technical activities n.e.c. Ixelles · balance sheet 80,498 €
Frequently asked questions about Immunofusion
What is the revenue of Immunofusion?
Immunofusion files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Immunofusion?
In Belgium, the VAT number is the company number prefixed with BE: BE0804563629 for Immunofusion, if the company is VAT-registered. Its company number (CBE) is 0804.563.629.
Where is the registered office of Immunofusion?
According to the CBE register, the registered office of Immunofusion is in 6041 Charleroi.
What is the equity of Immunofusion?
At the close of the 2025 financial year, the equity of Immunofusion amounts to -126,049 €, a solvency of -392.3% of total assets.
Who manages Immunofusion?
The register lists 2 active mandates at Immunofusion. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Immunofusion
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →